400 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Intact Investment Management Inc.

Intact Investment Management Inc. purchased a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 400 shares of the company’s stock, valued at approximately $65,000.

Several other institutional investors also recently modified their holdings of ZTS. Atala Financial Inc purchased a new stake in Zoetis during the 4th quarter valued at about $60,000. LBP AM SA grew its position in Zoetis by 19.6% during the 4th quarter. LBP AM SA now owns 112,801 shares of the company’s stock valued at $18,379,000 after purchasing an additional 18,483 shares during the last quarter. PGGM Investments grew its position in Zoetis by 91.8% during the 4th quarter. PGGM Investments now owns 58,528 shares of the company’s stock valued at $9,536,000 after purchasing an additional 28,005 shares during the last quarter. Lazard Freres Gestion S.A.S. grew its position in Zoetis by 20.6% during the 4th quarter. Lazard Freres Gestion S.A.S. now owns 1,074,865 shares of the company’s stock valued at $175,127,000 after purchasing an additional 183,912 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its position in Zoetis by 9.4% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 376,173 shares of the company’s stock valued at $61,030,000 after purchasing an additional 32,204 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Stock Performance

ZTS opened at $161.33 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market cap of $72.24 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 2.78 and a beta of 0.94. The company’s 50 day moving average is $166.82 and its 200 day moving average is $176.15. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.